GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control

References

• Utsunomiya K. Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance. Vasc Health Risk Manag. 2012;8:429–436.
   PubMedGoogle Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular out comes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Mita T, Katakami N, Yoshii H, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39(1):139–148.
   PubMed Web of Science ®Google Scholar
• Mita T, Katakami N, Shiraiwa T, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care. 2016;39(3):455–464.
   PubMed Web of Science ®Google Scholar
• Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59(4):1030–1037.
   PubMed Web of Science ®Google Scholar
• Goto H, Nomiyama T, Mita T, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun. 2011;405(1):79–84.
   PubMed Web of Science ®Google Scholar
• Terawaki Y, Nomiyama T, Kawanami T, et al. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol. 2014;13:154.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration, Seshasai SR, Kaptoqe S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364(9):829–841.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685.
   PubMed Web of Science ®Google Scholar
• Hotta N, Nakamura J, Iwamoto Y, et al. Cause of death in Japanese diabetics based on the results of a survey of 18,385 diabetics during 1991-200 –report of committee on cause of death in diabetes mellitus. J Japan Diab Soc. 2007;50(1):47–61. Japanese.
   Google Scholar
• Kasuga M, Ueki K, Tajima N, et al. Report of the Japan Diabetes Society/Japanese Cancer association joint committee on diabetes and cancer. Cancer Sci. 2013;104(7):965–976.
   PubMed Web of Science ®Google Scholar
• Poloz Y, Stambolic V. Obesity and cancer, a case for insulin signaling. Cell Death Dis. 2015;6:e2037.
   PubMed Web of Science ®Google Scholar
• Pal A, Barber TM, Van De Bunt M, et al. PTEN mutation as a cause of constitutive insulin sensitivity and obesity. N Eng J Med. 2012;367(11):1002–1011.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17(8):328–336.
   PubMed Web of Science ®Google Scholar
• Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem. 2012;68(4):701–711.
   PubMed Web of Science ®Google Scholar
• Park J, Scherer PE. Leptin and cancer: from cancer stem cells to metastasis. Endocr Reat Cancer. 2011;18(4):C25–C29.
   PubMed Web of Science ®Google Scholar
• Barb D, Williams CJ, Neuwirth AK, et al. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86(Suppl):858S–866S.
   PubMed Web of Science ®Google Scholar
• Nomiyama T, Perez-Tilve D, Ogawa D, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007;117(10):2877–2888.
   PubMed Web of Science ®Google Scholar
• Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014;37:131–141.
   PubMed Web of Science ®Google Scholar
• Chan Y-C, Chuang L-M. The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res. 2010;2(3):316–331.
   PubMed Web of Science ®Google Scholar
• Nomiyama T, Tanaka Y, Hattori N, et al. Accumulation of somatic mutation in mitochondrial DNA extracted from peripheral blood cells in diabetic patients. Diabetologia. 2002;45(11):1577–1583.
   PubMed Web of Science ®Google Scholar
• Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des. 2008;14(10):940–945.
   PubMed Web of Science ®Google Scholar
• Goto A, Noda M, Sawada N, et al. High hemoglobin A1c levels within the non-diabetic range are associated with risk of all cancers. Int J Cancer. 2016;138(7):1741–1753.
   PubMed Web of Science ®Google Scholar
• Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012;7(3):e0033411.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Rosato V, Buniato D, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist. 2013;18(2):148–156.
   PubMed Web of Science ®Google Scholar
• Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin dependent) diabetes. Diabetologia. 1986;29(1):46–52.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture. Diabetes. 2015;64(2):317–326.
   PubMed Web of Science ®Google Scholar
• Chiu W-Y, Shih S-R, Tseng C-H. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Exp Diabetes Res. 2012;2012:1–7.
   Google Scholar
• Lamari Y, Boissard C, Moukhtar MS, et al. Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett. 1996;393(2–3):248–252.
   PubMed Web of Science ®Google Scholar
• Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012;153(3):1538–1547.
   PubMed Web of Science ®Google Scholar
• Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97(1):121–131.
   PubMed Web of Science ®Google Scholar
• Jung MJ, Kwon SK. Expression of glucagon-like peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance. Endocrinol Metab (Seoul). 2014;29(4):536–544.
   PubMedGoogle Scholar
• Hegedüs L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96(3):853–860.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Madsen LW, Anderson S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid c-cells causing calcitonin release and c-cell proliferation. Endocrinology. 2010;151(4):1473–1486.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62(10):3316–3323.
   PubMed Web of Science ®Google Scholar
• Koehler JA, Drucker DJ. Activation of Glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes. 2006;55(5):1369–1379.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wei R, Wang L, et al. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. Am J Physiol Endocrinal Metab. 2014;306(12):E1431–E1441.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang L, Wei R, et al. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes Metab. 2014;16(9):850–860.
   PubMed Web of Science ®Google Scholar
• Kothare PA, Linnebjerg H, Isaka Y, et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol. 2008;48(12):1389–1399.
   PubMed Web of Science ®Google Scholar
• Cases AI, Ohtsuka T, Kimura H, et al. Significance of expression of glucagon-like peptide-1 receptor in pancreatic cancer. Oncol Rep. 2015;34(4):1717–1725.
   PubMed Web of Science ®Google Scholar
• Hou Y, Ernst SA, Heidenreich K, et al. Glucagon-like peptide −1 receptor is present in pancreatic cancer cells and regulates amylase secretion through cAMP. Am J Physiol Gastrointest Liver Physiol. 2016;310(1):G26–G33.
   PubMed Web of Science ®Google Scholar
• Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012;57(6):1576–1585.
   PubMed Web of Science ®Google Scholar
• Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann NY Acad Sci. 2012;1271:37–43.
   PubMed Web of Science ®Google Scholar
• Koehler JA, Kain T, Drucker DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology. 2011;152(9):3362–3372.
   PubMed Web of Science ®Google Scholar
• Koehler JA, Baggio LL, Yusta B, et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Matab. 2015;21(3):379–391.
   PubMed Web of Science ®Google Scholar
• Kissow H, Hartmann B, Holst JJ, et al. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept. 2012;179(1–3):91–100.
   PubMedGoogle Scholar
• Emmert-streib F, De Matos Simoes R, Glazko G, et al. Functional and genetic analysis of the colon cancer network. BMC Bioinformatics. 2014;15(Suppl 6):S6.
   PubMed Web of Science ®Google Scholar
• Ligumsky H, Wolf I, Israeli S, et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat. 2012;132(2):449–461.
   PubMed Web of Science ®Google Scholar
• Fidan-Yaylah G, Dodurga Y, Secme M, et al. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol. 2016;37(2):2647–2653.
   Web of Science ®Google Scholar
• Luciani P, Deledda C, Benvenuti S, et al. Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells. PLoS One. 2013;8(8):e71716.
   PubMed Web of Science ®Google Scholar
• Chen B-D, Zhao W-C, Jia Q-A, et al. Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model. Int Mol Sci. 2013;14(12):24293–24304.
   PubMed Web of Science ®Google Scholar
• Nomiyama T, Kawanami T, Irie S, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014;63(11):3891–3905.
   PubMed Web of Science ®Google Scholar
• Lutz SZ, Staiger H, Fritsche A, et al. Antihyperglycaemic therapies and cancer risk. Diab Vasc Dis Res. 2014;11(6):371–389.
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–2411.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Wittert G. Androgens, diabetes and prostate cancer. Endocr Relat Cancer. 2012;19(5):F47–F62.
   PubMed Web of Science ®Google Scholar
• Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 2009;124(6):1398–1403.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071–1078.
   PubMed Web of Science ®Google Scholar
• Mitin T, Chen M-H, Zhang Y, et al. Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol. 2011;186(6):2233–2237.
   PubMed Web of Science ®Google Scholar
• Moses KA, Utuama OA, Goodman M, et al. The association of diabetes and positive prostate biopsy in a US veteran population. Prostate Cancer Prostatic Dis. 2012;15(1):70–74.
   PubMed Web of Science ®Google Scholar
• Rastmanesh R, Hejazi J, Marotta F, et al. Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms. Clin Genitourin Cancer. 2014;12(3):143–148.
   PubMed Web of Science ®Google Scholar
• Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med. 1989;321(3):129–135.
   PubMed Web of Science ®Google Scholar
• Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039–1047.
   PubMed Web of Science ®Google Scholar
• Fan W, Yanase T, Morinaga H, et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem. 2007;282(10):7329–7338.
   PubMed Web of Science ®Google Scholar
• Eyre H, Kahn R, Robertson RM, et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Diabetes Care. 2004;27(7):1812–1824.
   PubMed Web of Science ®Google Scholar
• Badrick E, Renehan AG. Diabetes and cancer: 5 years into the recent controversy. Eur J Cancer. 2014;50(12):2119–2125.
   PubMed Web of Science ®Google Scholar
• Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583.
   PubMed Web of Science ®Google Scholar
• Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46(13):2369–2380.
   PubMed Web of Science ®Google Scholar
• Sahra IB, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576–3586.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Nomiyama T, Kawanami T, et al. Combined treatment with Exendin-4 and metformin attenuates prostate cancer growth. PLoS One. 2015;10(10):e0139709.
   PubMed Web of Science ®Google Scholar
• Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:1–19.
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA. 2015;112(30):E4111–E4119.
   PubMed Web of Science ®Google Scholar
• Tanabe M, Nomiyama T, Motonaga R, et al. Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese hospital database. BMC Endocr Disord. 2015;15:49.
   PubMed Web of Science ®Google Scholar